Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery... see more

Recent & Breaking News (OTCQB:CYTOF)

Auris Medical Announces Transfer to Nasdaq Capital Market

GlobeNewswire September 28, 2017

Auris Medical Provides Board of Directors Update

GlobeNewswire September 26, 2017

Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus

GlobeNewswire September 22, 2017

Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27

GlobeNewswire September 20, 2017

Auris Medical to Host Scientific Symposium at the AAO-HNSF Annual Meeting

GlobeNewswire September 5, 2017

Auris Medical Announces Receipt of Nasdaq Notice

GlobeNewswire August 24, 2017

Investor Network: Auris Medical Holding AG to Host Earnings Call

Accesswire August 10, 2017

Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017

GlobeNewswire August 3, 2017

Auris Medical Completes Acquisition of AM-125 Assets

GlobeNewswire July 20, 2017

Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness

GlobeNewswire July 5, 2017

Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris

GlobeNewswire June 22, 2017

Auris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City

GlobeNewswire May 31, 2017

How These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma

PR Newswire May 18, 2017

Investor Network: Auris Medical Holding AG to Host Earnings Call

Accesswire May 11, 2017

Auris Medical Provides Business Update and Reports First Quarter 2017 Financial Results

GlobeNewswire May 11, 2017

Auris Medical Reports Key Results from Keyzilen® AMPACT1 Open-Label Extension Study

GlobeNewswire May 9, 2017

Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017

GlobeNewswire May 4, 2017

Auris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study

GlobeNewswire April 24, 2017

Auris Medical Announces Receipt of Nasdaq Notice of Bid Price Deficiency

GlobeNewswire March 31, 2017

Auris Medical to Present at the 16th Annual Needham Healthcare Conference on April 5

GlobeNewswire March 29, 2017